Publications

1. Advice - reimburse mirikizumab (Omvoh®) for the treatment of ulcerative colitis

   The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to reimburse mirikizumab (Omvoh®) ...

   Report | 07-08-2024

2. Advice - reimburse omalizumab (Xolair®) for the treatment of severe asthma

   The National Health Care Institute has advised the Minister of Health, Welfare and Sport to reimburse omalizumab (Xolair®) from ...

   Report | 05-08-2024

3. Advice - reimburse empagliflozin (Jardiance®) for treating Von Gierke disease and Fanconi-Bickel syndrome

   The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to extend the reimbursement ...

   Report | 02-08-2024

4. Advice - reimburse baricitinib (Olumiant®) for treatment of severe alopecia areata

   The National Health Care Institute has advised the Minister of Health, Welfare and Sport to reimburse baricitinib (Olumiant®) ...

   Report | 31-07-2024

5. Advice - reimburse cipaglucosidase alfa (Pombiliti®) in combination with miglustat (Opfolda®) for the treatment of Pompe disease

   The National Health Care Institute has advised the Minister of Health, Welfare and Sport to reimburse cipaglucosidase alfa ...

   Report | 30-07-2024

6. Advice - do not reimburse teclistamab (Tecvayli®) for the treatment of multiple myeloma

   The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to not reimburse teclistamab ...

   Report | 10-07-2024

7. Advice - reimburse dostarlimab (Jemperli®) for the treatment of endometrial cancer

   The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to reimburse dostarlimab ...

   Report | 10-07-2024

8. Advice - reimburse sacituzumab govitecan (Trodelvy®) for the treatment of breast cancer (re-evaluation)

   The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to reimburse sacituzumab govitecan ...

   Report | 09-07-2024

9. Advice - reimburse naldemedine (Rizmoic®) for the treatment of constipation due to the use of strong analgesics (opioids)

   The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to reimburse naldemedine (Rizmoic ...

   Report | 01-07-2024

10. Advice - extending the reimbursement of axicabtagene ciloleucel (Yescarta®) for the treatment of lymphoma

    The National Health Care Institute has advised the Minister for Medical Care to extend the reimbursement of axicabtagene ...

    Report | 26-06-2024